Publications by authors named "I Visman"
Article Synopsis
- The study investigates the potential of using DNA methylation patterns in peripheral blood to predict response to adalimumab (ADA) treatment in rheumatoid arthritis (RA) patients, as current biomarkers are lacking.
- Researchers analyzed DNA methylation in 92 RA patients before starting ADA and classified them as responders or non-responders after 6 months based on disease activity scores.
- A machine learning model successfully distinguished responders from non-responders with an accuracy of 76% using a set of 27 specific DNA markers associated with immune function in RA.
Objective: To study changes in retention of first biologic disease-modifying antirheumatic drug (DMARD) therapy over a period of 15 years in an inception cohort of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
Methods: We assessed patient and disease characteristics and drug survival of patients starting a biologic (tumor necrosis factor inhibitor [TNFi]) therapy between 2004 and 2019 in routine care at the Amsterdam Rheumatology and Immunology Center, Reade, the Netherlands. Starts were classified as early (2004-2008), intermediate (2009-2013), and recent (2014-2018).
Objective: To examine the prevalence of hip involvement between sexes in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) and to estimate the effect of TNFi on radiographic progression of hip involvement compared to the spine.
Methods: Two hundred ninety-nine patients with AS treated with TNFi (215 men; median age: 43 yrs [IQR 36-52], median disease duration: 7.6 yrs [IQR 2-15]) were evaluated for hip involvement, defined radiographically as Bath AS Radiological Hip Index (BASRI-hip) score ≥ 2.
Article Synopsis
- Anti-TNF therapies are used to treat patients with inflammatory rheumatic diseases like ankylosing spondylitis (AS) and may impact cardiovascular health positively.
- A study analyzed the renal function of 211 AS patients treated with anti-TNF, measuring changes in estimated glomerular filtration rate (eGFR) over time.
- Results indicated a slight decline in eGFR, but it was not clinically significant, and anti-TNF treatment was deemed safe for kidney function in AS patients, regardless of pre-existing renal risk factors.